# US 2010/0168003 A1 · Agent for Treating Polyglutamine Aggregation-Caused Disease or Suppressing Onset Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168003 A1
- Document ID: US20100168003A1
- Status: Published application
- Kind: A1
- Application number: 12/226,447
- Filed: 2007-03-30
- Published: 2010-07-01
- Earliest claimed: 2006-04-20
- Assignees: Osaka University; Kringle Pharma Inc.
- Inventors: Toshikazu Nakamura; Hiroshi Funakoshi; Daisuke Miyazawa; Kunio Iwatani
- Web page: https://patentgrep.com/patent/US20100168003A1

## CPC

- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention discloses an agent for treating a polyglutamine aggregation-caused disease or suppressing its onset, which comprises, as an active ingredient, (1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or (2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

## Claims

### Claim 1

An agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof, comprising, as an active ingredient,
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 2 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein the active ingredient is (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 3 (depends on 2)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 2, wherein the DNA encoding HGF protein is DNA containing (a) DNA comprising a base sequence represented by SEQ ID NO: 1, 2 or 5, or (b) DNA which encodes a protein that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of the above-mentioned (a) under a stringent condition.

### Claim 4 (depends on 2)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 2, wherein the DNA is inserted into herpes simplex virus type 1 (HSV-1) vector, adenovirus vector or adeno-associated virus vector.

### Claim 5 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein the active ingredient is (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them.

### Claim 6 (depends on 5)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 5, wherein the HGF protein has (a) a same amino acid sequence that is represented by SEQ ID NO: 3, 4 or 6, or (b) an amino acid sequence that is substantially equal to the above-mentioned amino acid sequence.

### Claim 7 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein the polyglutamine aggregation-caused disease is at least one disease selected from the group consisting of Huntington's disease, spinal and bulbar muscular atrophy, type 1, 2, 3, 6, 7 and 12 of spinocerebellar ataxia, dentatorubral-pallidoluysian atrophy and the like.

### Claim 8 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein the polyglutamine aggregation-caused disease is Huntington's disease.

### Claim 9 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein the agent is used for topical administration to an area affected by the polyglutamine aggregation-caused disease.

### Claim 10 (depends on 9)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 9, wherein the topical administration is intrathecal administration.

### Claim 11

An agent for inhibiting ventricular dilatation, comprising, as an active ingredient,
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 12

An agent for inhibiting neurodegeneration or cell death dependent on a gene product responsible for a polyglutamine aggregation-caused disease, comprising, as an active ingredient,
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 13

An agent for inhibiting caspase-3 and/or caspase-1 activation in a neuron, comprising, as an active ingredient,
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 14

An agent for inhibiting a processing of a gene product responsible for a polyglutamine aggregation-caused disease, comprising, as an active ingredient,
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 15 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein an effect on treating the polyglutamine aggregation-caused disease or suppressing the onset thereof results from inhibiting ventricular dilatation.

### Claim 16 (depends on 15)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 15, wherein the ventricular dilatation is caused by striatal neurodegeneration or cell death dependent on a gene product responsible for the polyglutamine aggregation-caused disease.

### Claim 17 (depends on 16)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 16, wherein the striatal neurodegeneration or cell death is caused by caspase-3 and/or caspase-1 activation.

### Claim 18 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein an effect on treating the polyglutamine aggregation-caused disease or suppressing the onset thereof results from neurogenesis.

### Claim 19 (depends on 1)

The agent for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof according to claim 1, wherein an effect on treating the polyglutamine aggregation-caused disease or suppressing the onset thereof results from inhibiting a processing of a gene product responsible for the polyglutamine aggregation-caused disease.

### Claim 20

A method for a manufacture of a therapeutic agent, which comprises using a
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 21

A method for treating a polyglutamine aggregation-caused disease or suppressing an onset thereof, comprising an administration to a mammal of
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 22

(canceled)

### Claim 23

A method for inhibiting ventricular dilatation, comprising an administration to a mammal of
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 24

(canceled)

### Claim 25

A method for inhibiting neurodegeneration or cell death dependent on a gene product responsible for a polyglutamine aggregation-caused disease, comprising an administration to a mammal of
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 26

(canceled)

### Claim 27

A method for inhibiting caspase-3 and/or caspase-1 activation in a neuron, comprising an administration to a mammal of
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.

### Claim 28

(canceled)

### Claim 29

A method for inhibiting a processing of a gene product responsible for a polyglutamine aggregation-caused disease, comprising an administration to a mammal of
(1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or
(2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.
